AKUMSAkums Drugs & Pharmaceuticals Ltd.

    Akums Drugs & Pharmaceuticals Ltd: results and news

    Every Akums Drugs & Pharmaceuticals Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, legal.

    2 articles · pharmaceuticals · Latest 2 Nov 2026

    A gloved hand drips liquid from a glass pipette into a small vial in a laboratory.

    AKUMSAkums Drugs & Pharmaceuticals Ltd.

    Akums Drugs & Pharmaceuticals Q2 FY27 Results: Consolidated Net Profit ₹115 Crore on Total Income of ₹1,371 Crore

    Akums Drugs & Pharmaceuticals (NSE: AKUMS) reported total income of ₹1,371.29 crore and net profit of ₹114.57 crore on a consolidated basis for the quarter ended 30 Sep 2026, and standalone total income of ₹420.84 crore and net profit of ₹32.64 crore, it said in a filing on 02 Nov 2026.

    • Earnings
    • pharmaceuticals

    Blacklitt Research3 min read

    AKUMSAkums Drugs and Pharmaceuticals Limited

    Akums’ subsidiary receives an NPPA demand notice of ₹52.75 crore on a Hetero-marketed injection, and says the marketer is liable

    Akums Drugs and Pharmaceuticals Limited has told the exchanges that its wholly owned subsidiary, Pure and Cure Healthcare Private Limited, received a demand notice dated 13 Oct 2026 from the National Pharmaceutical Pricing Authority (NPPA). The notice concerns Lanol 1000 mg injection (100 ml), which Pure and Cure manufactures for its client Hetero Healthcare Limited, the marketer. It says Hetero fixed the product's maximum retail price above the limits under the Drugs (Prices Control) Order, 2013.

    • Legal
    • Pharmaceuticals

    Blacklitt Research2 min read